FDA to Review Letermovir for CMV Disease Prevention in Kidne

The FDA has accepted for review two sNDAs for Prevymis (letermovir).

Related Keywords

Nicholas Kartsonis , Merck Prevymis , Global Clinical Development , Merck Research Laboratories , Drug Administration , Priority Review , New Drug Application , Prescription Drug User Fee Act , Merck Research , Accessed February ,